{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NTLA",
  "name": "Intellia Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/NTLA/",
  "json_url": "https://frontierpicks.com/dossiers/NTLA.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "view_source": "research",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Intellia Therapeutics is more likely to lag the S&P 500 over three months: the FDA decision on its hereditary angioedema gene-editing drug lonvo-z, due 10 March 2027, falls after that window, while losses widen and partner revenue falls.",
  "invalidation_trigger": "A daily close above $12.00, back over the 50-day average, which would show the shares leading into the 2027-03-10 FDA decision; or an FDA approval of lonvo-z before that date.",
  "kill_line_kind": "price_line",
  "kill_line_due": null,
  "catalyst_date": "2026-12-07",
  "catalyst_estimated": false,
  "portfolio": null,
  "pick": null,
  "themes": [
    "rare-disease-gene-therapy",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "Intellia reports no product revenue; all revenue is from collaborations, so quarterly revenue reflects partner accounting rather than demand.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-05"
    },
    {
      "claim": "The company has a secured term loan facility of up to $400 million with OrbiMed, and diluted shares rose 27.2% from a year earlier in the third quarter of 2026.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-05"
    }
  ],
  "source_links": [
    {
      "title": "Intellia Therapeutics, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001652130/000119312526448673/ntla-ex99_1.htm",
      "date": "2026-11-05"
    },
    {
      "title": "Intellia stock price target maintained at $30 by Citizens on HAE data",
      "url": "https://za.investing.com/news/stock-market-news/intellia-stock-price-target-maintained-at-30-by-citizens-on-hae-data-93CH-4573299",
      "date": "2026-11-13"
    },
    {
      "title": "NTLA Stock Quote Price and Forecast",
      "url": "https://www.cnn.com/markets/stocks/NTLA",
      "date": null
    },
    {
      "title": "Intellia Therapeutics Reports Q3 2026 Results, $615M Cash and $127.5M Net Loss",
      "url": "https://www.tradingview.com/news/tradingview:c9f2231bc8ea1:0-intellia-therapeutics-reports-q3-2026-results-615m-cash-and-127-5m-net-loss/",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "The FDA accepted the lonvo-z Biologics License Application with Priority Review and a target action date of 2027-03-10, and is not currently planning an advisory committee.",
      "source": "Intellia third-quarter 2026 results release (8-K exhibit 99.1)",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Collaboration revenue was $7.2 million in the third quarter of 2026, against $13.8 million a year earlier, mainly because of lower Regeneron revenue.",
      "source": "Intellia third-quarter 2026 results release (8-K exhibit 99.1)",
      "as_of": "2026-11-05"
    },
    {
      "claim": "The third-quarter 2026 net loss was $127.5 million, against $101.3 million a year earlier; general and administrative expense rose to $46.1 million from $30.5 million.",
      "source": "Intellia third-quarter 2026 results release (8-K exhibit 99.1)",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Cash, equivalents and marketable securities were $614.8 million at 2026-09-30, which the company says funds operations at least into 2028.",
      "source": "Intellia third-quarter 2026 results release (8-K exhibit 99.1)",
      "as_of": "2026-11-05"
    },
    {
      "claim": "In September 2026 Intellia signed a senior secured term loan facility of up to $400 million with OrbiMed.",
      "source": "Intellia third-quarter 2026 results release (8-K exhibit 99.1)",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Citizens kept a Market Outperform rating and a $30 target after the ACAAI lonvo-z data, citing two-thirds of patients attack-free.",
      "source": "Investing.com, Citizens note report",
      "as_of": "2026-11-13"
    },
    {
      "claim": "JPMorgan raised its Intellia price target to $9 from $8.",
      "source": "CNN Markets analyst summary",
      "as_of": "2026-11-09"
    },
    {
      "claim": "The chief executive sold 9,000 shares at $11.99 on 2026-11-02 under a Rule 10b5-1 plan.",
      "source": "SEC Form 4 filed 2026-11-03",
      "as_of": "2026-11-03"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-20",
    "business": "Intellia develops one-time CRISPR gene-editing treatments delivered inside the body: lonvo-z for hereditary angioedema and nex-z, with Regeneron, for transthyretin amyloidosis. It has no product sales yet. Revenue comes from collaborations: $7.2 million in the quarter to 2026-09-30.",
    "change": {
      "now": "In September 2026 the FDA accepted the lonvo-z application with Priority Review and set a 2027-03-10 action date, the company reported on 2026-11-05; it plans a US launch in the first quarter of 2027.",
      "next": "General and administrative expense rose to $46.1 million in the third quarter of 2026 from $30.5 million a year earlier as the company built its field force; the net loss widened to $127.5 million.",
      "linked": "If approved, lonvo-z competes with Takeda (TAK), BioCryst (BCRX), Ionis (IONS) and KalVista (KALV) in HAE; Regeneron (REGN) shares nex-z economics, and its revenue to Intellia fell in the quarter."
    },
    "priced_in": "At the 2026-11-19 close (filed inputs to 2026-11-05) the shares trade at EV/sales 17.7 and P/B 2.2, for an enterprise value of $936 million and a free-cash-flow yield of −26.8%. That holds only if lonvo-z wins approval and a launch revenue ramp starts to close a free cash outflow of $358 million over four quarters.",
    "priced_in_filed": null,
    "links": {
      "customers": [
        {
          "ticker": "REGN",
          "url": "https://frontierpicks.com/dossiers/REGN/"
        }
      ],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "TAK",
          "url": null
        },
        {
          "ticker": "BCRX",
          "url": null
        },
        {
          "ticker": "IONS",
          "url": null
        },
        {
          "ticker": "KALV",
          "url": null
        },
        {
          "ticker": "ALNY",
          "url": null
        },
        {
          "ticker": "BBIO",
          "url": null
        },
        {
          "ticker": "PFE",
          "url": "https://frontierpicks.com/dossiers/PFE/"
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-20",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-20",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "value_musd": 7.2,
              "yoy_pct": -48
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "value_musd": 7.7,
              "yoy_pct": -46.2
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-11",
              "restated": null,
              "value_musd": 15,
              "yoy_pct": -9.5
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "value_musd": 23,
              "yoy_pct": 78.8
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": null,
              "value_musd": 13.8,
              "yoy_pct": 51.3
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "value_musd": 14.2,
              "yoy_pct": 104.8
            }
          ]
        },
        "gross_margin": {
          "status": "not reported"
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "pct": -1707.7
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "pct": -1472.3
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-11",
              "restated": null,
              "pct": -668.1
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": -428.9
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": null,
              "pct": -808.9
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "pct": -772.2
            }
          ]
        },
        "pretax_income": {
          "status": "not reported"
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "four_quarters_end": "2026-09-30",
          "value_musd": -127.5,
          "four_quarters_musd": -426.1
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": -355.2
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 2.9
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": -358.1
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "base_end": "2025-09-30",
          "pct": 27.2
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 474.1
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 73.7,
          "composition": "long-term debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 400.4
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 0,
          "yoy_pct": -100
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 7.5
        },
        "inventory": {
          "status": "not reported"
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 613.1
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-30",
          "basis_filed": "2026-11-05",
          "value_musd": 1403.6
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-30",
          "basis_filed": "2026-11-05",
          "value_musd": 1003.2
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-30",
          "basis_filed": "2026-11-05",
          "multiple": 19
        },
        "ev_ebit": {
          "status": "not meaningful"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-30",
          "basis_filed": "2026-11-05",
          "multiple": 2.3
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-30",
          "basis_filed": "2026-11-05",
          "pct": -25.5
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 31.61,
      "days_to_cover": 11.1,
      "change_pct": -0.2
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\n\nIntellia Therapeutics is more likely to lag the S&P 500 over the next three months. Its main value event, the FDA decision on lonvo-z (lonvoguran ziclumeran) for hereditary angioedema (HAE), is due on 2027-03-10. That date falls just after the 63-session window. Until then the shares carry a cash burn of $358 million over four quarters and partner revenue that is shrinking. The rating is Low because the shares fell after good news. Positive lonvo-z data at the ACAAI meeting on 2026-11-12 were followed by a close of $9.70 on 2026-11-13, down from $10.55 the session before.\n\nThe drug looks strong on its own terms. The company's 2026-11-05 results release says the FDA accepted the Biologics License Application (BLA) in September with Priority Review and does not plan an advisory committee. It also says the company plans a US launch in the first quarter of 2027. The near-term problem is the gap between that approval and any revenue. In the meantime, the filed numbers show losses getting wider and the share count rising.\n\n## Bull Case\n\n- **Priority Review, with no advisory panel planned.** The FDA set a target action date of 2027-03-10 and told the company it is not planning an advisory committee, according to the 2026-11-05 third-quarter release.\n- **Data that support a one-time treatment.** Citizens reported on 2026-11-13 that two-thirds of patients in the ACAAI 2026 update were attack-free and 100% were free of long-term preventive therapy. The firm kept its $30 target and assigns $20 a share to the HAE opportunity.\n- **Funding reaches beyond the launch.** The company reported $614.8 million in cash, equivalents and marketable securities at 2026-09-30. It says that funds operations at least into 2028, before lonvo-z revenue and before further draws on an OrbiMed term loan of up to $400 million signed in September 2026.\n- **Second Phase 3 program fully enrolled.** MAGNITUDE-2, which tests nex-z (nexiguran ziclumeran) in hereditary transthyretin amyloidosis with polyneuropathy, finished enrolling in the third quarter of 2026 with more than the targeted 60 patients, per the 2026-11-05 release.\n\n## Bear Case\n\n- **Partner revenue is falling fast.** Collaboration revenue was $7.2 million in the quarter to 2026-09-30, down 48.0% from a year earlier. The company attributes the drop mainly to lower revenue from Regeneron.\n- **Losses widen as launch costs build.** The third-quarter net loss was $127.5 million, against $101.3 million a year earlier. General and administrative expense rose to $46.1 million from $30.5 million, while research spending fell to $83.3 million from $94.7 million (2026-11-05 release).\n- **Dilution and new debt.** Diluted shares rose 27.2% from a year earlier in the quarter to 2026-09-30. The 10-Q filed 2026-11-05 shows $74 million of long-term debt.\n- **Most analysts are cautious.** BofA Securities kept a Hold rating on 2026-11-14. JPMorgan raised its target to $9 from $8 on 2026-11-09, which is below the 2026-11-19 close of $9.52.\n- **Planned insider selling continues.** SEC Form 4 filings show the chief executive sold 9,000 shares at $11.99 on 2026-11-02 and 22,675 shares at an average of $12.65 on 2026-08-20 and 2026-08-21, all under a Rule 10b5-1 plan.\n\n## Setup & Price Structure\n\nIntellia closed at $9.52 on 2026-11-19. That is 48.5% below the 52-week intraday high of $18.48 set on 2026-07-02. On adjusted daily closes, the shares sit below the 50-day average of $11.70 and the 200-day average of $12.89, and they are down 25.9% over three months from a reference close of $12.84 on 2026-08-21.\n\nThe latest fall came after good news. The shares closed at $10.55 on 2026-11-12, the day of the ACAAI data and the investor webcast, then fell to $9.70 on 2026-11-13. They have stayed between $9.52 and $9.86 since. The 52-week closing low is $8.04 from 2025-11-20.\n\nA common market view is that biotech shares drift lower before an FDA decision and then rally into it. Across US stocks, no reliable effect has been found so far after one-day drops of this kind. The case therefore rests on the calendar and on the cash figures.\n\n## Catalyst Calendar\n\n- **2026-12-07:** Intellia at the 23rd Global Cardiovascular Clinical Trialists Forum, Washington, D.C. (2026-12-07 to 2026-12-09). Any update on the timing of the nex-z Phase 3 trial in cardiomyopathy would change how much value sits beyond lonvo-z.\n- **~2027-02-26 (est.):** Fourth-quarter and full-year 2026 results. Shows the year-end cash, the term-loan draws and the 2027 spending plan going into launch.\n- **2027-03-10:** FDA target action date for lonvo-z in hereditary angioedema. Approval and the approved label decide whether the planned first-quarter 2027 launch happens; this is the event the case turns on.\n\n## What Would Change Our Mind\n\nA daily close above $12.00, back over the 50-day average, which would show the shares leading into the 2027-03-10 FDA decision; or an FDA approval of lonvo-z before that date.\n\n## Correlation Notes\n\nThe shares trade on events: the FDA date, data presentations and launch news. Partner economics matter too, because Regeneron (REGN) co-develops nex-z and was the main source of the revenue decline. In HAE, lonvo-z would compete with preventive treatments from Takeda (TAK), BioCryst (BCRX) and Ionis (IONS) and with KalVista's (KALV) on-demand therapy. In transthyretin amyloidosis, nex-z would face Alnylam (ALNY), BridgeBio (BBIO) and Pfizer (PFE). How investors price gene-editing companies in general also moves the shares.",
  "first_seen": "2026-11-19",
  "last_analyzed": "2026-11-20T03:37:36+00:00",
  "last_synthesized": "2026-11-20",
  "date_modified": "2026-11-20",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}